This strategy combines LDLR upregulation-mediated cholesterol transport machinery priming with engineered endosomal escape mechanisms to achieve superior CNS antibody delivery. The approach begins with targeted pharmacological or gene therapy-based upregulation of LDLR expression in brain microvascular endothelial cells, which primes the cellular cholesterol transport infrastructure and enhances co-expressed LRP1 receptor density and trafficking efficiency. Therapeutic antibodies are conjugated to high-affinity APOE-mimetic peptides that specifically target the upregulated LRP1 receptors, facilitating rapid receptor-mediated endocytosis across the blood-brain barrier. The critical innovation involves engineering these antibody-APOE conjugates with pH-responsive fusogenic peptides that remain inactive at physiological pH (7.4) but undergo conformational activation in the acidic endosomal environment (pH 5.5-6.0). Upon endocytosis, the acidification-triggered fusogenic domains disrupt endosomal membranes, liberating therapeutic antibodies directly into the cytoplasm and preventing lysosomal degradation.

This strategy combines LDLR upregulation-mediated cholesterol transport machinery priming with engineered endosomal escape mechanisms to achieve superior CNS antibody delivery. The approach begins with targeted pharmacological or gene therapy-based upregulation of LDLR expression in brain microvascular endothelial cells, which primes the cellular cholesterol transport infrastructure and enhances co-expressed LRP1 receptor density and trafficking efficiency. Therapeutic antibodies are conjugated to high-affinity APOE-mimetic peptides that specifically target the upregulated LRP1 receptors, facilitating rapid receptor-mediated endocytosis across the blood-brain barrier. The critical innovation involves engineering these antibody-APOE conjugates with pH-responsive fusogenic peptides that remain inactive at physiological pH (7.4) but undergo conformational activation in the acidic endosomal environment (pH 5.5-6.0). Upon endocytosis, the acidification-triggered fusogenic domains disrupt endosomal membranes, liberating therapeutic antibodies directly into the cytoplasm and preventing lysosomal degradation. This dual-priming mechanism leverages LDLR's well-characterized transcytotic machinery to enhance LRP1-mediated transport capacity while simultaneously solving the post-transcytotic degradation problem through engineered endosomal escape. The strategy predicts 50-200 fold improvements in CNS antibody bioavailability compared to passive FcRn transport, with quantifiable, dose-dependent relationships between LDLR expression levels and therapeutic delivery efficiency. This approach is particularly advantageous for neurodegenerative disease therapeutics where consistent, high-concentration CNS penetration is essential for clinical efficacy.